Interviews with 57 people across Cameroon's chemotherapy supply chain found weak regulation, underfunded regulatory work and high prices encouraging substandard cancer medicines and treatment.
Published as "Barriers to accessing high-quality cancer medicines in Cameroon. A qualitative study of the views and practices of regulators and frontline healthcare providers". A cross-sectional qualitative study combining a document review with interviews of 57 stakeholders working in regulation, procurement, quality control and use of chemotherapy: 25 pharmacists, 14 medical oncologists, 12 oncology nurses, five drug distributors and one regulator, interviewed in Yaoundé and Douala in October 2023.
Cancer medicines in Cameroon are often paid for by families, and the people who regulate and use them describe a market where cheaper products of uncertain quality fill the gap.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/